BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Liraglutide

An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.

1.0k+ PubMed studies analyzed · 479 RCTs · Evidence Score: 76.7

Research Domains

Liraglutide has been studied across 13 research domains including 🔥 Metabolic, 🧬 Hormones, ❤️ Cardiovascular, 🫁 Liver & Detox, 🫘 Kidney. The primary research focus is 🔥 Metabolic with 96% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Liraglutide, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Gabapentin
2 shared targets
Zanamivir
2 shared targets
Hydromorphone
2 shared targets
trolox
2 shared targets
Oseltamivir
2 shared targets
Nitroarginine
2 shared targets
Oxytocin
2 shared targets
Pregabalin
2 shared targets
hydrocodone
2 shared targets
Lamivudine
2 shared targets
Loading evidence profile...

This evidence profile for Liraglutide is generated deterministically from 1,001 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.